Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(17%)

Results Posted

0%(0 trials)

Terminated

1(17%)

Phase Distribution

Ph not_applicable

33%

Ph phase_2

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Recruiting1

Not yet recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 21 (33.3%)

N/A2 (66.7%)

Trials by Status

completed350%

recruiting117%

not_yet_recruiting117%

terminated117%

Recent Activity

1 active trials

Showing 5 of 6

recruiting

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

NCT00112749

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT07667686

French Validation of the Recovery Assessment Scale (RAS-FR)

Recruiting

NCT06871345Not Applicable

Perimenstrual Symptoms and Emotional Dysregulation in Autism

Not Yet Recruiting

NCT04816734Not Applicable

Initial Parenteral Nutrition Education of Parent Assessment Plan

Completed

NCT04600206

Existential Distress in Patients with Advanced Cancer and Their Caregivers

Completed

NCT00112749Phase 2

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Terminated

NCT02450240

Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders

Completed

All 6 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 6